Clinical trials: Treatment Resistant Schizophrenia
Schizophrenia, Treatment-resistant Schizophrenia
Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis
SchizOMICS is a Phase IV, multicenter, dose-flexible, open-label, randomized controlled clinical trial to evaluate the efficacy and safety of aripiprazole versus paliperidone using multi-omics data in patients with a first…
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Side Effect, Lipid Metabolism Disorders
- Trial name
- SchizOMICS (NCT06060886)
- Testing
- Aripiprazole, Paliperidone
- Volunteers
- 244 people
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Schizophrenia; Psychosis, Metabolic Syndrome
Adjunctive Use of Fute (Flupentixol) in Multi-acting Receptor-targeted Antipsychotics Treated Schizophrenia Patients
Fute (Flupentixol) combined with MARTAs (Multiple-Acting Receptor Targeted Antipsychotics) drugs has its clinical efficacy toward positive symptoms and might reduce the metabolic syndrome-related factors in patients.
- Conditions
- Schizophrenia; Psychosis, Metabolic Syndrome, Flupentixol, Antipsychotic Agents
- Trial name
- NCT04898270
- Testing
- Flupentixol, Multi-acting receptor-targeted antipsychotics (MARTAs)
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Taichung Veterans General Hospital
Metabolic Syndrome, Female
Berberine Treat Metabolic Syndrome in Schizophrenia
In early clinical study investigators confirmed that berberine could prevent glucose and lipid metabolism disorder in schizophrenia, so investigators intend to verify the effect and safety of berberine in treatment for metabolic…
- Conditions
- Metabolic Syndrome, Female, Schizophrenia
- Trial name
- NCT03251716
- Testing
- berberine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tianjin Anding Hospital
Treatment Resistant Schizophrenia, Schizophrenia
Magnetic Seizure Therapy for Schizophrenia - Trial
This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).
- Conditions
- Treatment Resistant Schizophrenia, Schizophrenia, Schizoaffective Disorder
- Trial name
- MAST (NCT06672588)
- Testing
- Magnetic Seizure Therapy (MST), Electroconvulsive Therapy (ECT)
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- Centre for Addiction and Mental Health
Hallucinations, Schizophrenia
Multimodal MRI-guided rTMS to Treat Refractory Hallucinations
The efficacy of neuro-navigated rTMS for patients with schizophrenia suffering from drug-resistant multisensory hallucinations will be tested by the implementation of a double-blind randomized controlled trial (RCT) This study…
- Conditions
- Hallucinations, Schizophrenia, Perceptual Disorders
- Trial name
- MULTIMODHAL (NCT01373866)
- Testing
- MagPro X100 repetitive Transcranial Magnetic Stimulation
- Where
- 2 sites in France
- Volunteers
- 85 people
- Sponsor
- University Hospital, Lille
Schizophrenia
Augmenting Clozapine With Sertindole - SERCLOZ
The purpose of the study is to determine whether addition of sertindole to clozapine treatment can improve psychosis or the metabolic side-effects of clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT00345982
- Testing
- Serdolect
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Schizophrenia, Schizoaffective Disorder
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
This study will investigate the safety and efficacy of quetiapine in sub-optimally responding patients with DSM-IV schizophrenia using a double blind, randomized 12-week trial comparing oral doses of 1200 mg/d to 600 mg/d of…
- Trial name
- HDQ (NCT00297947)
- Testing
- quetiapine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Manhattan Psychiatric Center
Sialorrhea
Clozapine-induced Hypersalivation - Feasibility Trial
A randomised placebo-controlled feasibility study of glycopyrrolate and hyoscine in the treatment of clozapine-induced hypersalivation to assess recruitment and retention rates in a multi-centre trial.
- Trial name
- GOTHIC1 (NCT02613494)
- Testing
- Hyoscine, Glycopyrrolate
- Where
- 2 sites in United Kingdom
- Volunteers
- 29 people
- Sponsor
- Mersey Care NHS Trust
Metabolic Syndrome
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart disease and type 2 diabetes.
- Trial name
- ATOMICS (NCT00794963)
- Testing
- Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan, As selected by community physician
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Northwell Health
Obesity, Metabolic Syndrome X
Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue
To examine if 3 months of treatment with a GLP-1 (glucagon-like-peptide-1) analogue can induce weight loss in obese, non-diabetic patients with a diagnosis within the schizophrenic spectrum.
- Conditions
- Obesity, Metabolic Syndrome X, Drug-induced Obesity, Schizophrenia
- Trial name
- TAO (NCT01794429)
- Testing
- Exenatide
- Where
- Denmark
- Volunteers
- 45 people
- Sponsor
- Bjorn H. Ebdrup
Bipolar Affective Disorder, Schizophrenia Disorders
Medical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients
This observational study will characterise the general psychiatric and general medical phenotypes of 100 adults, sequentially admitted to NHS General Adult Psychiatry (GAP) "mental health" inpatient wards, providing the first…
- Conditions
- Bipolar Affective Disorder, Schizophrenia Disorders, Depression Disorders, Personality Disorders
- Trial name
- NCT07398365
- Testing
- Questionnaires, rating scales, & review of notes
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Edinburgh
Schizophrenia
Famotidine in Schizophrenia
Objective of the trial is to study if famotidine add-on treatment is more effective than placebo add-on in reducing symptoms of schizophrenia among patients receiving insufficient response to ongoing antipsychotic treatment.
- Trial name
- NCT01946295
- Testing
- Famotidine
- Where
- 6 sites in Finland, Sweden
- Volunteers
- 140 people
- Sponsor
- Jesper Ekelund
Cardiovascular Side Effects of Clozapine, Neutropenia Due to Clozapine
Nor)Clozapine Kinetics and Side Effects in Therapy Resistant Schizophrenia and the Optimal Sampling Time for Therapeutic Drug Monitoring
The goal of this observational study is to better understand how clozapine treatment can be tailored as regards minimizing side effects and optimizing efficacy and monitoring.
- Conditions
- Cardiovascular Side Effects of Clozapine, Neutropenia Due to Clozapine, General Side Effects of Clozapine, Constipation Due to Clozapine
- Trial name
- COTTONS (NCT06749041)
- Volunteers
- 60 people
- Sponsor
- GGZ Noord-Holland-Noord
Psychosis, Schizophrenia Disorder
Comparison of Accelerated Intermittent Theta Burst Stimulation vs High Frequency Transcranial Magnetic Stimulation (Hf-rTMS) on Cognitivesymptoms in Treatment-resistant Schizophrenia
This randomized, double-blind, sham-controlled trial compares three brain stimulation approaches-accelerated intermittent theta burst stimulation (aITBS), high-frequency repetitive transcranial magnetic stimulation (HF-rTMS), and…
- Trial name
- DB RCT (NCT07445620)
- Testing
- Accelerated iTBS, High-Frequency rTMS
- Where
- India
- Volunteers
- 90 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Treatment Resistant Schizophrenia
Reduction of Auditory-Verbal Hallucinations in Schizophrenia Through Cortical Neuromodulation
Approximately 1% of the general population will be affected by schizophrenia over the course of their lives, with life expectancy being reduced by 20 years on average and quality of life being severely diminished in affected…
- Trial name
- HALLUSTIM (NCT06361160)
- Testing
- Active Transcranial Magnetic Stimulation (TMS)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia
A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia
Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long term treatment of clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT00154258
- Testing
- Clozapine
- Volunteers
- 19 people
- Sponsor
- Novartis
Treatment-resistant Schizophrenia
SMART Design to Compare Antipsychotic Treatments in Treatment-Resistant Schizophrenia
The project intends to take treatment-resistant schizophrenia as the research object and uses sequential multiple assignment randomized trial(SMART) design to define the treatment recommendations of different drug regimen for…
- Trial name
- NCT04528095
- Testing
- Clozapine, MECT, DBS
- Where
- China
- Volunteers
- 162 people
- Sponsor
- Shanghai Mental Health Center
Psychosis, Intellectual Disability
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
This clinical trial will prove whether a large number of people with intellectual disability and treatment-resistant psychosis could benefit from the use of clozapine.
- Trial name
- CLOZ-AID (NCT04529226)
- Testing
- Clozapine, haloperidol, pimozide, olanzapine, risperidone, amisulpride
- Where
- 20 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Treatment-resistant Schizophrenia
Efficacy and Safety of Temporal Interference Stimulation in Treatment-Resistant Schizophrenia: An Exploratory Study.
This exploratory study aims to evaluate the preliminary efficacy and safety of temporal interference (TI) stimulation in patients with treatment-resistant schizophrenia (TRS).
- Trial name
- NCT07773831
- Testing
- Temporal Interference Stimulation
- Volunteers
- 20 people
- Sponsor
- Zhimin Wang
Schizophrenia
The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.
The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia. Is it effective and efficacious?
- Trial name
- ATHSCHIZ (NCT05623228)
- Testing
- The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia
- Where
- Greece
- Volunteers
- 35 people
- Sponsor
- Rakitzi, Stavroula